455 E. MEDICAL CENTER BLVD, HOUSTON, TX
Appoints Kathleen 'Kate' Rubins, Ph.D. to Board of Directors
Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FibroBiologics, Inc. Approves 2026 Equity and Incentive Compensation Plan
FibroBiologics Enters At The Market Offering Agreement with H.C. Wainwright
Stock Options Granted to Executives at FibroBiologics, Inc.
Annual Report to Security Holders
FibroBiologics Enters At The Market Offering Agreement for $6.15 Million
Compliant with All Nasdaq Listing Requirements
Amended Annual Report
FY 2024
Q3
Q2
Q1
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement